Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differences in growth rate and therapeutic response between tumors growing at different sites

International Journal of Oncology

Volumn 29, Issue 5, 2006, Pages 1087-1094

  Tsujie, Masanori ^a   Uneda, Shima ^a   Tsai, Hilda ^a   Seon, Ben K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenesis; Antibody based therapy; Endoglin; Tumor heterogeneity; Vascular targeting therapy

Indexed keywords

CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOLOGY; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 39049176805     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.5.1087     Document Type: Article

References (36)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Denekamp J: Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181-196, 1993.
3. Bicknell R and Harris AL: Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 3: 399-407, 1992.
4. Ruoslahti E: Specialization of tumour vasculature. Nat Rev Cancer 2: 83-90, 2002.
5. Brekken RA, Li C and Kumar S: Strategies for vascular targeting in tumors. Int J Cancer 100: 123-130, 2002.
6. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427, 2004.
7. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31-36, 1991.
8. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
9. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
10. Wachsberger P, Burd R and Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanism of interaction. Clin Cancer Res 9: 1957-1971, 2003.
11. Gasparini G, Longo R, Fanelli M and Teicher BA: Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23: 1295-1311, 2005.
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizmab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
13. Haruta Y and Seon BK: Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 83: 7898-7902, 1986.
14. Gougos A and Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141: 1925-1933, 1988.
15. Seon BK: Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer 99: 310-311, 2002.
16. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M and Bernabeu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23: 2340-2345, 1993. (Pubitemid 23265903)
17. Schmidt-Weber CB, Letarte M, Kunzmann S, Ruckert B, Bernabeu C and Blaser K: TGF-β signaling of human T cells is modulated by the ancillary TGF-β receptor endoglin. Int Immunol 17: 921-930, 2005. (Pubitemid 41417959)
18. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ and De Waal RM: A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 100: 27-34, 1993.
19. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES and Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995. (Pubitemid 26030991)
20. Seon BK, Matsuno F, Haruta Y, Kondo M and Barcos M: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with anti-human endoglin immunotoxin. Clin Cancer Res 3: 1031-1044, 1997. (Pubitemid 27319748)
21. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Muller R and Adamkiewicz J: Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81: 568-572, 1999. (Pubitemid 29203054)
22. Matsuzaki H, Haruta Y and Seon BK: Effect of induced transformation of human leukemia cells on the expression of GP160, a novel human leukemia-associated cell surface glycoprotein. Fed Proc 46: 1056, 1987.
23. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J and Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54: 363-370, 1993. (Pubitemid 23169671)
24. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB and Wendel DP: Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537, 1999. (Pubitemid 129524435)
25. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, Charlton R, Parums DV, Jowett T, Marchuk DA, Burn J and Diamond AG: Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 217: 42-53, 2000. (Pubitemid 30046798)
26. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J and Letarte M: Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
27. Smirnov DA, Foulk BW, Doyle GV, Connelly MC, Terstappen LW and O'Hara SM: Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res 66: 2918-2922, 2006.
28. Tabata M, Kondo M, Haruta Y and Seon BK: Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 82: 737-742, 1999. (Pubitemid 29356974)
29. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M and Seon BK: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 5: 371-382, 1999. (Pubitemid 29085191)
30. Seon BK, Negoro S and Barcos MP: Monoclonal antibody that defines a unique human T-cell leukemia antigen. Proc Natl Acad Sci USA 80: 845-849, 1983.
31. Folkman J: Antiangiogenesis agents. In: Cancer: Principles and Practice of Oncology. 6th edition. De Vita VT Jr, Hellman S and Rosenberg SA (eds). Williams & Wilkin, Lippincott, PA, pp509-519, 2001.
32. Takahashi N, Haba A, Matsuno F and Seon BK: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61: 7846-7854, 2001.
33. Shiozaki K, Harada N, Greco WR, Haba A, Uneda S, Tsai H and Seon BK: Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in non-human primates and effects of doxorubicin. Cancer Immunol Immunother 55: 140-150, 2006.
34. Jung YD, Ahmad SA, Akagi Y, Takahashi Y, Liu W, Reinmuth N, Shaheen RM, Fan F and Ellis LM: Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev 19: 147-157, 2000.
35. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
36. Fidler IJ, Langley RR, Kerbel RS and Ellis LM: Angiogenesis. In: Cancer: Principles and Practice of Oncology. 7th edition. DeVita VT Jr, Hellman S and Rosenberg SA (eds). Williams & Wilkin, Lippincott, PA, pp129-137, 2005.